NEUROENDOCRINE TUMORS OF THE CERVIX


Cite item

Full Text

Abstract

Редкие формы рака шейки матки, в частности светлоклеточная, мукоэпидермоидная, нейроэндокринные и другие, встречаются в 1—1,5% наблюдений и отличаются высокой степенью злокачественности и агрессивным течением заболевания. В статье представлены эпидемиология и патоморфологическая характеристика данных опухолей, выделены их основные маркеры. Также приведены основные виды лечения при указанной патологии и данные выживаемости пациенток в зависимости от вида проведенного лечения.

About the authors

S. O Nikogosyan

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

115478, Moscow, Russian Federation

T. Sh Tagibova

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

Email: assya21@mail.ru
аспирант отд-ния гинекологии 115478, Moscow, Russian Federation

V. V Kuznetsov

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

115478, Moscow, Russian Federation

O. A Anurova

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

115478, Moscow, Russian Federation

Z. N Khizriyeva

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences

115478, Moscow, Russian Federation

References

  1. Ceplin M., Kvols L. (eds.) Neuroendocrine tumors: a guide for physicians (translation from English), Moscow., Practical medicine. 2011: 11; 17—19; 23; 37; 43; 54; 88; 100 (in Russian). (Кэплин М., Кволс Л. (ред.) Нейроэндокринные опухоли: руководство для врачей: [пер. с англ.] Москва: Практическая медицина. 2011: 11; 17—19; 23; 37; 43; 54; 88; 100.)
  2. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13, 715 carcinoid tumors. Cancer. 2003; 97(4): 934-59.
  3. Surveillance, Epidemiology, and End Results (SEER), Program 2005 Public-use Data (1973-2002). National Cancer Institute, DC-CPS, Surveillance Research Program, Cancer Statistics Branch. National Cancer Institute, Bethesda, MD. (Released April 2005, based on the November 2004 submission.)
  4. Simonenko V.B., Dulin P.A., Makanin M.A. Neuroendocrine tumors. Moscow. 2010: 6, 16 (in Ryssian). (Симоненко В.Б., Дулин П.А., Маканин М.А. Нейроэндокринные опухоли. Москва. 2010: 6; 16.)
  5. Viswanathan A.N., Deavers M.T., Jhingran A., Ramirez P.T., Levenback C., Eifel P.J. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol. Oncol. 2004; 93: 27-33.
  6. Crowder S., Tuller. Small cell carcinoma of the female genital tract. Semin. Oncol. 2007; 34: 57—63.
  7. Lee J.M., Lee K.B., Nam J.H. et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: Results of a multi-center retrospective Korean study. Ann Oncol. 2008; 19: 321-6.
  8. Tsunoda S., Jobo T., Arai M. et al. Small-cell carcinoma of the uterine cervix: A clincopathologic study of 11 cases. Int. J. Gynecol. Cancer. 2005; 15:295-300.
  9. Boruta D.M., Schorge J.O., Duska L.A. et al. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol. Oncol. 2001; 81: 82—7.
  10. Lee S.W., Nam J.H., Kim D.Y., Kim J.H., Kim K.R., Kim Y.M., Kim Y.T. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int. J. Gynecol. Cancer. 2010; 20: 411-6.
  11. Chen J., MacDonald O.K., Gaffney D.K. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol. 2008; 111: 1394-14.
  12. Ruoslahti E. Integrins. J. Clin. Invest. 1991; 87: 1—5.
  13. Albelda S.M. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Invest. 1993; 68: 4—17.
  14. Kumar C.C. Signaling by integrin receptors. Oncogene. 1998; 17: 1365—73.
  15. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell. Mol. Life Sci. 1998; 54: 541—8.
  16. Sanders R.J., Mainiem F., Giancotti F.P. The role of integrins in tumorogenesis and metastasis. Cancer Invest. 1998; 16: 329—44.
  17. Reig Castillejo A., Membrive Conejo I., Foro Arnalot P., Rodríguez de Dios N., Algara López M. Neuroendocrine small cell carcinoma of the uterine cervix. Clin Transl Oncol. 2010 Jul; 12 (7): 512—3.
  18. Bermudez A., Vighi S., Garcia A., Sardi J. Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge. Gynecol. Oncol. 2001; 82: 2—9.
  19. Chan J.K., Loizzi V., Burger R.A., Rutgers J., Monk B.J. Prognostic factors in neuroendocrine small cell cervical carcinoma: A multivariate analysis. Cancer. 2003; 97: 568-74.
  20. Cohen J.G., Chan J.K., Kapp D.S. The management of small-cell carcinomas of the gynecologic tract. Curr Opin Oncol. 2012 Sep; 24(5): 572—9. doi: 10.1097/CCO.0b013e3283565ed6.
  21. Zivanovica O., Leitao M.M., Parkb K.J., Zhaob H., Diaza J.P., Konnerd J., Alektiarc K., Chia D.S., Abu-Rustuma N.R., Aghajaniand C. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy, Gynecologic Oncology. Volume 112, Issue 3, March 2009; 590-3.
  22. Rossi A., Maione P., Palazzolo G., Sacco P.C., Ferrara M.L., Falanga M., Gridelli C. Review New targeted therapies and smallcell lung cancer. Clin Lung Cancer. 2008 Sep; 9 (5): 271—9.
  23. Tian W.J., Zhang M.Q., Shui R.H. Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix. Oncol Lett. 2012 January; 3 (1): 125-130. Published online 2011 October 12. doi: 10.3892/ol.2011.439
  24. Kim Y.B., Barbuto D., Lagasse L.D., Karlan B.Y. Successful treatment of neuroendocrine small cell carcinoma of the cervix metastatic to regional lymph nodes. Gynecol Oncol. 1996 Sep; 62 (3): 411—4.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies